The use of antisense oligonucleotides as therapeutic agents has generated considerable enthusiasm in the research and medical community. Antisense oligonucleotides as therapeutic agents were proposed as far back as in the 1970s when the antisense strategy was initially developed. Nonetheless, it has taken almost a quarter of a century for this potential to be realized. The principle of antisense technology is the sequencespecific binding of an antisense oligonucleotide to target mRNA, resulting in the prevention of gene translation. The specificity of hybridization by Watson-Crick base pairing make antisense oligonucleotides attractive as tools for targeted validation and functionalization, and as therapeutics to selectively modulate the expression of genes involved in the pathogenesis of diseases. The last few years have seen a rapid increase in the number of antisense molecules progressing past Phase I, II and III clinical trials. This review outlines the basic concept of the antisense technology, its development and recent potential therapeutic applications.
INTRODUCTION
AS-ODs, thus, are unmodified or chemically modified ssDNA, RNA or their analogs (1). They are 13-25 nucleotides long and are specifically designed to hybridize to corresponding RNA by Watson-Crick binding [4] .
A quarter of a century since the first report that antisense oligonucleotides (AS-ODs) could inhibit gene expression in a sequence-specific manner [1,2], antisense (AS) inhibition of gene expression has reliesd primarily on the simple rules of Watson-Crick base pairing of nucleic acids. A synthetic small single-stranded oligonucleotide (OD) that is complementary to a specific gene, via hybridization to corresponding mRNA, inhibits the translation of that gene into protein, Fig. (1) , [3] .
AS-ODs have been called "the next great wave of the biotechnology revolution" and the "pharmacology of the future". Certainly from a theoretical point of view, the AS approach, in which the target pharmacophore is a specific sequence found in a specific mRNA, should have several advantages over traditional pharmaceuticals which target proteins [5] .
Among the characteristics that are essential for AS-ODs to be practically effective are their design and appropriate chemistry. These characteristics not only affect target hybridization, but also extra-and intracellular biological stability; their ability to avoid errant compartmentalization; and their efficient uptake and accumulation [6] . AS technology has rapidly developed as a powerful research tool, resulting in enormous opportunities for its therapeutic application. Indeed, one AS drug already exists and several more are in advanced clinical trials [7] .
The AS-OD technology represents a "new pharmacology". The receptor, mRNA, has never before been considered in the context of drug-receptor interactions. Before the advent of AS technology, no medicinal chemistry had been practiced on the putative "drugs", ODs. The basis of the drug-receptor interaction, Watson-Crick hybridization, had never been considered as a potential binding event for drugs and put into a pharmacological context. Finally, postbinding events such as recruitment of nucleases to degrade the receptor RNA had never been considered from Pharmacological perspectives. A key to understanding AS technology is to consider it in a pharmacological context. It is essential to understand the structure, function, and metabolism of the receptors for these drugs. It is essential to consider the future in the context of advances in AS biology and medicinal chemistry that result in improved pharmacological behaviors [7] . (1) X = O, Phosphate; S, Phosphorothioate; Y = OH, H; B= nucleobase ( A, T, G or C).
HISTORY
foundation for AS research and re-establish an interest in phosphate backbone modifications as approaches to improve the properties of ODs [8] . Despite the observations of Miller, Ts'o and Zamecnik interest in AS, research was quite limited until the late 1980s when advances in several areas provided technical solutions to a number of impediments.
As the design of AS-ODs require an understanding of the sequence of the RNA target, the explosive growth in availability of viral and human genomic sequences provided the information about which "receptor sequences" could be selected [8] .
Prior to the evolution of effective transfection methods and understanding of molecular biological techniques, DNA and RNA were administered as potential therapeutic agents. For example, DNA from several sources displayed antitumor activity and the activity was reported to vary as a function of size, base composition and secondary structure [8, 9] . However, the molecular mechanisms by which DNA might induce antitumor effect were never defined and numerous other studies failed to demonstrate antitumor activities with DNA [8] . In contrast to studies on DNA as a therapeutic agent, substantially more work has been reported on RNA and polyribonucleotides. Much of the effort focused on the ability of various polynucleotides to induce interferon, and the most thoroughly studied polynucleotide in this regard is polyriboinosine : polyribocytidine (poly rI:poly rC). Poly rI:poly rC was shown to have potent antiviral and antitumor activities in vitro and in vivo, which were attributed to interferon induction. The substantial toxicities of this polyribonucleotide in both animal and humans, however, limited its utility [8, 9] .
Over the past decade, substantial development in AS science, manufacturing, and development led to the approval of the first AS drug Fomivirsen (Vitravene TM ), (3), for the treatment of AIDS-related CMV retinitis [10, 11] . Furthermore, in the mean time, up to 50 new AS-ODs have entered phase I/II, and in some cases, phase III trials [7, 12] .
ANTI-mRNA STRATEGIES
Three types of anti-mRNA strategies can be distinguished. First, the use of single stranded AS-OD; second, the triggering of RNA cleavage through catalytically active ODs referred to as ribozymes; and finally, RNA interference (RNAi) induced by small interfering RNA (siRNA) molecules, which are summarized in Fig. (2) . The figure also demonstrates the difference between AS approaches and conventional drugs, most of which bind to proteins and thereby modulate their function. In contrast, AS agents act at the mRNA level, preventing its translation into protein. AS-ODs pair with their complementary mRNA, whereas ribozymes and DNA enzymes are catalytically active ODs that not only bind, but can also cleave their target RNA. In addition, RNAi has been established as a third, highly efficient method of suppressing gene expression in mammalian cells by the use of 21-23-mer siRNA molecules [13] [14] [15] [16] .
The other polyribonucleotide that has been studied extensively is ampligen, a mismatched poly rI: poly rC 12 U. This polyribonucleotide has been shown to induce interferon and to activate 2'-5' adenosine synthetase. Ampligen has similar properties to poly rI:poly rC, however, it has broader activities and lower toxicities and is still in development [8, 9] .
The first clear enunciation of the concept of exploiting AS-ODs as therapeutic agents was in the work of Zamecnik and Stephenson in 1978 [1,2]. They reported the synthesis of an oligodeoxyribonucleotide with 13 nucleotides long (2) that was complementary to a sequence in the respiratory syncytial virus genome.
A-A-T-G-G-T-A-A-A-A-T-G-G (2)
Despite the seemingly simple idea to reduce translation by ODs complementary to an mRNA, several problems have to be overcome for successful application. Accessible sites of the target RNA for OD binding have to be identified, AS Though less precisely focused on the therapeutic potential of AS-ODs, the work of Miller, Ts'o and their collaborators during the same period, helped to establish the 
agents have to be protected against nucleolytic attack, and their cellular uptake and correct intracellular localization have to be achieved. In recent years, considerable progress has been made towards the development of novel chemical modifications to stabilize ODs against nucleolytic degradation and enhance their target affinity [13] .
Fig. (2).
Comparison of different antisense strategies [13] . 
MECHANISM OF ACTION OF ANTISENSE OLIGONUCLEOTIDES
the three steps (initiation, elongation, and termination) required for translation has the potential to interrupt protein synthesis, Fig. (3) , [20, 21] . A general requirement for an AS-OD to be successful in mediating translational arrest appears to be a very high-affinity interaction between the OD and the targeted mRNA by Watson-Crick base pairing, thus sterically blocking the translation of a transcript into a protein.
Although there are multiple mechanisms by which an OD may terminate the activity of an RNA species to which it binds, evidence has been reported for two major mechanisms which contribute to the AS activity of ODs [12, [17] [18] [19] :
Translational Arrest by Blocking the Ribosome 4.2. Activation of RNase H
Prevention of binding of the protein translational machinery to the target mRNA by an AS-OD at any one of
The mechanism that was widely described is the destruction of AS-mRNA hybrids by an enzyme which gets activated, the RNase H [23, 24] . RNase H is a ubiquitous enzyme that degrades the RNA strand of an RNA-DNA duplex. It has been identified in organisms as diverse as viruses and human cells [7] . The precise recognition elements for RNase H are not known. However, ODs with DNA-like properties as short as tetramers can activate RNase H [25] . It is possible to take advantage of chimeric ODs designed to activate RNase H, with greater affinity for their RNA receptors, and to enhance specificity [26, 27] . Accordingly, most AS-ODs are designed to activate RNase H, which cleaves the RNA moiety of a DNA.RNA heteroduplex and therefore leads to degradation of the target mRNA, Fig. (4) . This mechanism has resulted in the most potent AS-ODs and is the best understood.
RNA through transesterification or hydrolysis reactions that result in cleavage of phosphordiester bonds, Fig. (5) , [29] .
A variety of ribozymes, catalyzing intramolecular splicing or cleavage reactions, has been found in lower eukaryotes, viruses and some bacteria. Different types of ribozymes and their mechanisms of action have been described comprehensively [31] [32] [33] .
The hammerhead ribozyme, which has been studied in great detail, is one of the most widely used catalytic RNA molecules. The hammerhead ribozyme was isolated from viroid RNA and its dissection into enzyme and substrate strands transformed this cis-cleaving molecule into a target specific trans-cleaving enzyme. It has a great potential for application in biological systems [34, 35] . This minimized hammerhead ribozyme is less than 40 nucleotides long and consists of two substrate binding arms and a catalytic domain, Fig. (6) .
A therapeutic OD that will specifically bind to and cleave an RNA target should be attractive. In order to achieve potential therapeutic utility of ribozymes, two approaches have been taken into account. The first approach, ribozymecoding sequence has been incorporated into plasmids and administered, which in effect uses a ribozyme gene therapy. Secondly, efforts are focused to identify the minimum ribozyme structure combined with chemical modifications that retain ribozyme activity while enhancing stability to nucleases [35, 37, 38] .
Substantial progress has been reported with regard to the synthesis and testing of nuclease-resistant ribozyme drugs. Modifications including phosphorothioate (PS) and nucleoside analogs have been demonstrated to be incorporable in many sites in hammerhead ribozymes to increase nuclease resistance and support retained ribozyme activity [38] [39] [40] . Chemically stabilized ribozymes were taken up by cells in the synovial lining after intra-articular administration and reduced the target mRNA. Higher transfection efficiencies can, however, usually be achieved with delivery systems [41] . It is worthy to mention that some modified hammerhead ribozymes are currently in clinical trials, as is shown in section 13 [35, 42, 43] .
RNA INTERFERENCE (RNAi)
The recent discovery of RNAi has revolutionized biological research and now holds promise as a potential therapy for a wide variety of human diseases [43] [44] [45] [46] . RNAi is an innate cellular process that directs the degradation of mRNA homologous to short dsRNA termed siRNA. Recognition of the target mRNA by siRNA is based on standard Watson-Crick base pairing rules. Thus, it is another mechanism of AS gene regulation. Since the first description of this process in the nematode worm Caenorhabditis elegans, RNAi has become a powerful and widely used tool for gene functionalization [47] . Other mechanisms of RNA inactivation which are similar to the traditional AS mechanisms mediated by ribozymes and the recently described RNAi will be discussed in the following sections.
RNAi is initiated by long dsRNA molecules, which are processed into 21-23 nucleotide long RNAs by the Dicer enzyme, Fig. (7) . This RNase III protein is thought to act as a dimer that cleaves both strands of dsRNAs and leaves twonucleotide, 3' overhanging ends. These small interfering siRNAs are then incorporated into the RISC, a protein-RNA
RIBOZYMES
Ribozymes are RNA molecules that catalyze biochemical reactions [28] . Ribozymes cleave single-stranded regions in complex, and guide a nuclease which degrades the target RNA [12, 48] .
however, its application to mammalian cells was hampered by the fact that long dsRNA molecules induce an interferon response. This response triggers the degradation of mRNA by activation of RNase L and dsRNA-dependant protein This conserved biochemical mechanism could be used to study gene functions in a variety of model organisms, kinase, which generalizes inhibition of protein synthesis and activation of apoptotic pathway [49, 50] . Fortunately, this problem can be resolved by using smaller dsRNAs such as 21 nucleotide-long siRNA duplexes [51] . This finding has led to an explosion in the use of RNAi in mammalian cells, as it is thought to provide a significantly higher potency compared to traditional AS approaches. The first promising in vivo experiments with siRNA have already been performed and further therapeutically important genes are expected to be targeted soon. No toxic reactions after siRNA application have been observed in the studies performed to date, however, siRNAs may also exert off-target effects similar to PS-containing AS-ODs [12, 52] .
focus on the medicinal chemistry of ODs dates to perhaps a couple of years ago. The scope of medicinal chemistry has expanded enormously, but the biological data to support conclusions about synthetic strategies are only beginning to emerge [7] . One of the major challenges for AS approaches is the stabilization of ODs, as unmodified oligodeoxynucleotides are rapidly degraded in biological fluids by nucleases. The subjects of medicinal chemistry programs focus on approaches to create stronger and more selective affinity for RNA or duplex structures, to provide the ability to cleave nucleic acid target to enhance nuclease stability, cellular uptake and distribution, in vivo tissue distribution, metabolism, and clearance [12] .
TRIPLEX ANTISENSE TECHNOLOGY 8.1. Modifications of Antisense Oligonucleotides
A vast number of chemically modified nucleotides has been studied in AS experiments. A dimer of an OD depicting subunits that may be modified to enhance AS properties is shown in Fig. (9) . In general, three types of modifications of ribonucleotides can be distinguished: analogs with unnatural bases, modified sugars (especially at the 2' position of the ribose) or altered phosphate backbones [59] .
In the face of all this progress, still newer technologies are being developed based on concepts related to AS biology. For example, it is known that ODs can, in certain instances, bind to duplex DNA molecules through an unusual kind of base pairing, Fig. (8) . Triplex-forming ODs, chemically similar to AS-ODs, associate with dsDNA through non-Watson-Crick base pairing (Hoogsteen bonding) that generally depends on polypurine-rich tracts [53, 54] . In this triplex binding mode, ODs insert themselves into the major groove of the DNA double helix on a reasonably specific basis determined by the nucleotide sequence of the target DNA [56] . This triplex technology provides the opportunity to reduce gene transcription itself, rather than to destroy mRNA once it is produced. Because the triplex ODs can be made to permanently alter the DNA after localizing to specific target sites, the technology actually has the potential to permanently silence genes [54] . This strategy has been hindered by problems with both cell penetration and access to the densely packed nuclear DNA. Despite these problems, this technology has been used to introduce mutations into a gene in mice. This raises the interesting prospect of gene therapy to correct genetic abnormalities arising from point mutations [55, 57] . Furthermore, triplex technology may have important ramifications in the development of effective anticancer agents [54, 58] . 
MEDICINAL CHEMISTRY OF ANTISENSE OLIGONUCLEOTIDES

Modifications of Nucleobases
At the core of any rational drug discovery program is medicinal chemistry. Although the synthesis of modified nucleic acids has been studied for some time, the intense
The nucleobase or heterocycles of nucleic acids provide the recognition points for the Watson-Crick base pairing rules and any OD modification must maintain these specific hydrogen-bonding interactions. Therefore, the scope of nucleobase modifications is rather limited. Nevertheless, there are a number of base modified ODs that have been shown to be potentially useful. The relevant nucleobase modifications can be grouped into 2 structural classes[12,60,61] :
AS-ODs, one of the non-bridging oxygen atoms in the phosphodiester bond is replaced by sulfur (4). The introduction of PS linkages into ODs was primarily intended to enhance their nuclease resistance. PS-DNAs have a half-life in human serum of approximately 9-10 hs compared to ~1 h for unmodified oligodeoxynucleotides [62, 63] . In addition to nuclease resistance, PS-DNAs form regular Watson-Crick base pairs, activate RNase H, carry negative charges for cell delivery and display attractive pharmacokinetic properties [64] . The major disadvantage of PS-oligodeoxynucleotides, however, is their binding to certain proteins, particularly those that interact with polyanions such as heparin-binding proteins [65] [66] [67] [68] .
Nucleobase modifications providing a combination of effects are represented by 7-deaza-7-modified adenine and the tricyclic cytosine analogs having hydrogen-bonding capabilities in the major groove of heteroduplex. All these modifications are positioned to lie in the major groove of the heteroduplex. These may also have cationic interactions that stabilize duplex, do not greatly affect the sugar conformation of heteroduplex, provide little nuclease resistance, but will generally support an RNase H cleavage mechanism. In conclusion, the modification of nucleobases to obtain nuclease resistance might not be a fruitful approach [9, 12, 13, 61] .
Modifications of Sugar Moieties and Phosphate Backbones
The chemical modifications of ODs have mainly focused on the phosphodiester backbone and/or the sugar moiety. Consequently, AS-ODs are classified into three generations based on variations of these modifications [13] .
'First Generation' Antisense Oligonucleotides 8.1.2.2. 'Second Generation' Antisense
Oligonucleotides PS-oligodeoxynucleotides are the major representatives of first generation DNA analogs that are the best known and most widely used AS-ODs to date [7, 12] . In this class of
The problems associated with PS-oligodeoxynucleotides are to some degree solved in second generation ODs containing nucleotides with alkyl modifications at the 2' position of the ribose. 2'-O-Methyl (5) and 2'-Omethoxyethyl RNA (6) are the most important members of this class [13, 61] .
In one form of this disease, a mutation in intron 2 of the β-globin gene causes aberrant splicing of the pre-mRNA and, as a consequence, β-globin deficiency. A PS 2'-O-methyl OD that does not induce RNase H cleavage was targeted to the aberrant splice site and restored correct splicing, generating correct β-globin mRNA and protein in mammalian cells [71] .
AS-ODs made of these building blocks are less toxic than PS-DNAs and have a slightly enhanced affinity towards their complementary RNAs [64, 69] . These desirable properties are, however, counterbalanced by the fact that 2'-O-alkyl RNA cannot induce RNase H cleavage of the target RNA. Mechanistic studies of the RNase H reaction revealed that the availability of the 2'-OH group of the RNA are required for efficient RNase H cleavage [70] . Because 2'-Oalkyl RNA ODs do not recruit RNase H, their AS effect can only be due to a steric block of translation [13] .
Gapmer Technology
For most AS approaches, however, target RNA cleavage by RNase H is desired in order to increase AS potency. Therefore, 'chimeric strategy' or 'gapmer technology' has been developed [72] . Chimeric OD analogs bring together the beneficial properties of the two types of chemistry. In general, they have two segments: one that contains an OD derivative capable of activating RNase H and another that provides increased binding affinity and fewer side effects. Accordingly, gapmers consist of a central stretch of DNA or PS-DNA monomers and modified nucleotides such as 2'-Omethyl RNA at each end, Fig. (11) . The end blocks prevent nucleolytic degradation of the AS-OD, and the contiguous stretch of at least four or five deoxy residues between flanking Another approach, for which the OD must avoid activation of RNase H, is an alteration of splicing. In contrast to the typical role for AS-ODs in which they are supposed to suppress protein expression, blocking of a splice site with an AS-OD can increase the expression of an alternatively spliced protein variant. This technique is being developed to treat the genetic blood disorder, β-thalassemia.
2'-O-methyl nucleotides was reported to be sufficient for activation of Escherichia coli and human RNase H, respectively [73] . deoxyribose ring is replaced by a 3'-amino group (8). NPs exhibit both a high affinity towards a complementary RNA strand and nuclease resistance [80] .
'Third Generation' Antisense Oligonucleotides
Their potency as AS molecules have already been demonstrated in vivo, where a phosphoroamidate-OD was used to specifically down regulate the expression of the cmyc gene [81] . Moreover, the phosphoroamidates were found to be superior for the treatment of leukemia as compared to PS-ODs [82] . Because phosphoroamidates do not induce RNase H cleavage of the target RNA, they might prove useful for specific applications, where RNA integrity needs to be maintained, like modulation of splicing [13] .
In recent years, a variety of modified nucleotides has been developed to improve AS-OD properties such as target affinity, nuclease resistance and pharmacokinetics. The concept of conformational restriction has been used widely to enhance binding affinity and biostability. In analogy to the previous terms, 'first generation' for PS-DNA and 'second generation' for 2'-O-alkyl-RNA, these novel nucleotides will subsequently be subsumed under the term 'third generation' AS-ODs. DNA and RNA analogs with modified phosphate linkages or riboses as well as nucleotides with a completely different chemical moiety substituting the furanose ring have been developed. Promising examples of the vast body of novel modified nucleotides with improved properties will be discussed here, although further modifications may prove to have a great potential as AS molecules [13] .
ODs made of arabino nucleic acid, the 2'-epimer of RNA, or the corresponding FANA (9) were the first uniformly sugar-modified AS-ODs reported to induce RNase H cleavage of a bound RNA molecule [83] .
8.1.2.3.1. Peptide Nucleic Acids (PNAs)
PNAs belong to the first and most intensively studied DNA analogs besides PS-DNA and 2'-O-alkyl-RNA [74] [75] [76] . In PNAs, the sugar-phosphate backbone is completely replaced with a peptide-based backbone (7), [77] .
FANA-RNA duplex revealed a similar helical conformation to that of the corresponding DNA-RNA hybrid. The fluoro substituent is thought to project into the major groove of the helix, where it should not interfere with RNase H. Full RNase H activation by PS-FANA, however, was only achieved with chimeric ODs containing deoxyribonucleotides in the center, but the DNA stretch needed for high enzyme activity was shorter than in 2'-Omethyl gapmers [84] . The chimeric FANA-DNA ODs were highly potent in cell culture with a 30-fold lower IC 50 than the corresponding PS-OD [13] .
PNAs have favorable hybridization properties and high biological stability, but do not elicit target RNA cleavage by RNase H. Additionally, as they are electrostatically neutral molecules, solubility and cellular uptake are serious problems that have to be overcome for the usage of PNAs as AS agents to become practical. Improved intracellular delivery could be obtained by coupling PNAs to negatively charged oligomers, lipids, or certain peptides that are efficiently internalized by cells [74, 78] . According to in vivo studies performed recently, PNAs seem to be nontoxic, since they are uncharged molecules with low affinity for proteins that normally bind nucleic acids. The greatest potential of PNAs, however, might not be their use as AS agents, but their application to modulate gene expression by strand invasion of chromosomal duplex DNA [76, 79] .
Locked Nucleic Acid
One of the most promising candidates of chemically modified nucleotides developed in the last few years is the locked nucleic acid [85, 86] . Locked nucleic acid, LNA (10), is a ribonucleotide containing a methylene bridge that connects the 2'-oxygen of the ribose with the 4'-carbon [75, 87, 88] .
8.1.2.3.2. N3'-P5' Phosphoroamidates (NPs) Introduction of LNA into a DNA-OD induces a conformational change of the DNA-RNA duplex and prevents RNase H cleavage of the target RNA [89] . If degradation of NPs are another example of a modified phosphate backbone, in which the 3'-hydroxyl group of the 2'-the mRNA is intended, a chimeric DNA-LNA gapmer that contains a stretch of 7-8 DNA monomers in the center to induce RNase H activity should be used [64] . Chimeric 2'-O-methyl-LNA ODs that do not activate RNase H could be used as steric blocks to inhibit intracellular HIV-1 gene expression [90] .
intersubunit linkages are used instead of phosphodiester bonds (12).
MF-ODs are promising AS molecules that possess favorable hybridization, nuclease stability, and toxicity profiles. They do not prevent gene expression by activation of RNase H, rather, they function by translational arrest [98] [99] [100] [101] . Chimeric DNA-LNA ODs reveal an enhanced stability against nucleolytic degradation and an extraordinarily high target affinity [64, 91, 92] . This enhanced affinity towards the target RNA accelerates RNase H cleavage and leads to a much higher potency of chimeric DNA-LNA ODs in suppressing gene expression in cell culture, compared to PSDNAs or 2'-O-methyl modified [13] . 8.1.2.3.6. Cyclohexene Nucleic Acids (CeNAs).
Replacement of the five-membered furanose ring by a sixmembered ring is the basis for CeNAs (13) , which are characterized by a high degree of conformational rigidity of the oligomers.
AS-ODs containing LNA were also directed against human telomerase, which is an excellent AS target that is expressed in tumor cells but not in adjacent normal tissue. Telomerase is a ribonucleoprotein with an RNA component that hybridizes to the telomere and should therefore be accessible for AS-ODs. As RNA degradation is not necessary to block the enzyme's catalytic site, ODs unable to recruit RNase H should be suitable inhibitors of telomerase function. A comparative study revealed that LNAs have a significantly higher potential to inhibit human telomerase than PNAs [93] .
Full LNA-ODs were successfully used in vivo to block the translation of the large subunit of RNA polymerase II. These ODs inhibited tumor growth in a xenograft model with an effective concentration that was five times lower than was found previously for the corresponding PS-DNA [94] .
They form stable duplexes with complementary DNA or RNA and protect ODs against nucleolytic degradation [102] . In addition, CeNA-RNA hybrids have been reported to activate RNase H, albeit with a 600-fold lower k cat compared to a DNA-RNA duplex [103] . Therefore, the design of ODs with CeNA has a long way to go in order to obtain highly efficient AS agents. Tricyclo-DNA (14) is another nucleotide with enhanced binding to complementary sequences [104, 105] . As with most of the newly developed DNA and RNA analogs, tcDNA does not activate RNase H cleavage of the target mRNA. It was, however, successfully used to correct aberrant splicing of a mutated β-globin mRNA with a 100-fold enhanced efficiency relative to 2'-Omethylphosphorothioate RNA [106] . The most recently developed nucleosides as building blocks for AS-ODs are 2'-O,4'-C-Ethylene-Bridged Nucleic Acids (ENA), [95] . ENA (11) has a less-strained sixmembered ring in contrast to the five-membered ring of LNA. The corresponding ODs with ENA nucleosides retain a binding affinity to ssDNA and ssRNA as high as LNA and show excellent triplex formation with dsDNA. They also exhibit much higher nuclease-resistance than LNA [96, 97] . MF-ODs are nonionic DNA analogs, in which the ribose is replaced by a morpholino moiety and phosphoroamidate RNA. As a consequence, gapmers with a stretch of unmodified or PS-DNA monomers in the center of the OD are widely used. Several of the third generation nucleotides have already been used successfully in vivo, and a high AS potency combined with low toxicity has been observed. Therefore, one might expect that recent advances in nucleotide chemistry will soon lead to significant improvements of the AS compounds for target validation and therapeutic purposes.
Despite the significant improvements in the targeting efficiency in vitro of pendant ODs, only a limited number of in vivo experiments has been performed. Nevertheless, the value of conjugation chemistry has been clearly demonstrated both in vitro and in vivo [115, 116] .
Modifications of Ribozymes
In order to obtain therapeutic agents based on synthetic ribozymes, it is mandatory to chemically modify theses structures. These modifications, as in the traditional ASODs, should confer resistance to nucleases, selectivity, proper hybridization and uptake characteristics. In the case of ribozymes, the design of new modified nucleotides becomes more complex, since a proper folding of the nucleic acid is needed in order to maintain the catalytic activity. Several studies (X-ray structure elucidation and mapping with modified nucleotides) have shown that the presence of the 2'-hydroxyl group at specific positions in the catalytic core is essential for hydrolytic activity [61] .
Modification of Backbone Linkage Sites (2',5'-Oligonucleotides)
The 2',5'-backbone modified OD systems (15) are of interest, as their AS effects are achieved through a mechanism other than RNase H. They are a mediator of one of the interferon pathways and activate RNase L [107, 108] . A serious limitation restricting the potential utility of these AS-ODs is their rapid degradation by cellular nucleases [109] . However, it was reported that 2',5'-linked 3'-deoxyoligonucleotides have selective affinity to single stranded RNA with a markedly prolonged biological half life compared to 3',5'-liked DNA [110] .
In a comprehensive study, in which sequence-function relationships of the hammerhead ribozyme were analyzed, a great variety of modified nucleotides produced an optimized design for a stabilized hammerhead ribozyme, which is almost as active as its unmodified parent [13] . The nuclease resistant ribozyme contains five unmodified ribonucleotides, a 2'-C-allyl uridine (16) at position 4 and a 2'-O-methyl RNA at all remaining positions. In addition, the 3' end was protected by an inverted thymidine (17) . The serum half-life of the stabilized ribozyme is increased to more than 10 days compared to less than a 1 min half-life of the unmodified RNA ribozyme [40] . 
These unique ODs are reported to inhibit the activities of HIV-1 reverse transcriptase, DNA topoisomerase-I in HIV-1 infected cells [111, 112] , and suppress the replication of RSV [113] . Furthermore, there have been some recent efforts directed towards preparation of biologically stable analogs with a 2',5'-internucleotide connection for potential clinical applications [113] [114] [115] .
Pendant (Conjugated) Oligonucleotides
A slightly improved version of this ribozyme with four PS bonds in one substrate recognition arm and an inverted 3'-3' deoxy basic sugar led to the design presented in Fig.  (12) that is now used for clinical trials [40] .
In addition to the previously mentioned modifications, various molecules (pendants) have been attached (conjugated) to ODs to modify their pharmacokinetic properties. Other potential applications of pendants include increased solubility, lipophilicity, and ability to attach synthetic cleaver intercalaters (for improvement in binding affinity), cross-linking and alkylating groups [116] [117] [118] [119] [120] . Although conjugation of various functionalities (e.g. cholesterol, folic acid, fatty acids, bleomycins, etc.) to ODs has been reported to achieve these objectives, the data supporting some of the claims are limited and generalizations are not possible based on the data presently available [9,116,118].
General Structure-Activity/Property Relationships of Antisense Oligonucleotides
The excitement of ODs as drugs stems from the fact that, unlike other drug discovery approaches, they are informational materials. In other words, they are chemicals having a specific set of rules that clearly govern their binding to a specific nucleic acid receptor [59] . Like mentioned before, they bind to their nucleic acid target via WatsonCrick base-pairing rules. Consequently, the first test to determine whether a modified OD will be of interest is maintaining the sequence specificity according to WatsonCrick rules. A newly modified OD not possessing this fundamental specificity property is an immediate failure in the SAR study. The next step in the SAR study is to determine how tightly (binding affinity) the modified OD binds to its target nucleic acid. This property relates to the residence time that an OD is bound to its receptor. The next essential property that an OD must possess is sufficient resistance to degradation by exo-and endonucleolytic plasma and tissue nucleases [121] .
extensively studied [12] . PS-ODs and chimeric 2'-modified/DNA PS-ODs rapidly distribute to whole tissue with distribution half-lives ranging from 30 to 60 min in vivo [123] . Distribution from plasma is largely due to distribution to peripheral tissues. In contrast, ODs that do not contain a PS linkage, such as PNA, appear to be rapidly excreted in the urine. This difference in tissue distribution appears to be largely due to interactions with plasma proteins [124] .
First and second-generation PS-ODs are broadly distributed to all peripheral tissues. The highest concentrations of ODs are found in the liver, kidney, spleen, lymph nodes and bone marrow with no measurable distribution to the brain [125] . In general, the clearance rates result in half-lives of elimination ranging from 2 to 5 days in rodents and primates for first-generation ODs, with half lives increasing 5-10-fold for second-generation ODs [123, 126] . The elimination half-lives for second-generation ODs suggest that once weekly or even every two-week systemic dosing is feasible. First and second-generation PS-ODs not only distribute to tissues but also accumulate within cells in the tissues [127] . At early time points after injection, PS-ODs appear to be associated with extracellular matrix and within cells; however, by 24 hs, almost all of the ODs are found within cells in the tissues. The mechanism(s) by which ODs accumulate within cells following parenteral administration is(are) currently unknown. In summary, pharmacokinetic studies of PS-ODs demonstrate that they are well absorbed from parenteral sites, distribute broadly to all peripheral tissues, do not cross the blood-brain barrier, and are eliminated primarily by slow metabolism. In general, the pharmacokinetic properties of this class of compounds appear to be largely driven by chemistry rather than sequence [128] . Fig. (12) . Secondary structure model for a nuclease-resistant hammerhead ribozyme consists of 2'-O-methyl RNA (lower case),five ribonucleotides (upper case), a 2'-C-allyluridin at position 4, four PS linkages (s) and an inverted 3'-3' deoxabasic sugar. (H is any nucleotide except guanosine) [13] .
TOXICITY OF ANTISENSE OLIGONUCLEO-TIDES
There are two broad categories of potential toxicities for AS-ODs; toxicities due to exaggerated pharmacology and toxicities due to non-AS effects of the OD. The former category of side effects results from the OD binding to the desired target RNA or alternatively to non target RNA, producing an undesirable effect. Although this class of toxicity has not been a major issue for the technology, the potential for such toxicities can be further minimized by careful selection of the drug target and homology searches against human genomic databases [44] .
Further biophysical and biochemical properties that may be affected by OD modifications involve supporting of endonucleolytic cleavage of the RNA of a heteroduplex, chemical stability, lipophilicity, solubility, protein binding properties, toxicological properties and pharmacological properties [122] .
The second category of potential toxicities, that is non-AS effects, has been documented at higher doses of ODs. This later category of toxicities is related to the chemical class of ODs and can also exhibit some sequence specificity. PS-ODs are the best characterized class of ODs with regard to potential toxicities, having been examined extensively in a full range of acute, chronic and reproductive studies in rodents, lagomorphs and primates. In addition, well over 3000 patients have been exposed to PS-ODs in dozens of clinical trials. PS-ODs have proven to be safer than originally anticipated, yet, like any other drug, they might produce non-desirable effects at higher doses. The most probable mechanism of the observed toxicities is the binding of ODs to proteins. It should be noted that different patterns of toxicity exist between species. In rodents, the primary
In the past few years, modifications at nearly every position in ODs have been attempted and numerous potentially interesting analogs have been developed. Although it is far too early to determine which of the modifications may be most useful for particular purposes, it is clear that a wealth of new chemicals is available for systemic evaluation and that these studies should provide important insights into the SAR of AS-ODs [7] .
PHARMACOKINETICS OF ANTISENSE OLIGO-NUCLEOTIDES
The pharmacokinetics for PS-ODs (first generation ODs) and 2'-modified PS-OD (second generation ODs) have been toxicities of first-generation ODs occur after prolonged exposure to the ODs at doses above 10 mg/kg and appear to be a result of pro-inflammatory effects of the ODs. These effects are characterized by splenomegaly, lymphoid hyperplasia and diffuse multiorgan mixed mononuclear cell infiltrates [129] .
identification and validation of new drug targets and the potential therapeutic applications.
Application of Antisense Oligonucleotides in Functional Genomics and Target Validation
Most PS-ODs produce some immune stimulation in rodents, however, ODs containing specific sequence motifs can exhibit profound immune stimulation [130] . With careful OD design, the immune stimulatory effects can be minimized. A major attribute of second generation ODs is decreased immune stimulation in rodents [131] . In primates, the acute dose-limiting toxicities are a transient inhibition of the clotting cascade and the activation of the complement cascade [132] . Both of these toxicities are thought to be related to the polyanionic nature of the molecules, and the binding of these compounds to specific protein factors in plasma as such, relates to peak plasma concentration. Complement activation has been described primarily in nonhuman primates. To avoid the potential for complement activation, most studies have increased infusion times, or administered the drug by subcutaneous injection, with the goal of keeping peak plasma concentrations below a threshold concentration [133] .
The field of molecular biology has undergone a revolution in recent years, redefining the field as a data rich, as opposed to a data poor discipline. Two early and key steps in the process of identifying appropriate targets for drug discovery are to identify specific gene functions and develop an understanding of the role of a gene in contributing towards or maintaining a disease pathology (target validation). AS-ODs can be used to selectively manipulate the expression of a chosen gene or genes. Since mRNA detection and quantitation assays can be rapidly established for any gene, the most widely used AS mechanisms that can accomplish these goals are AS mechanisms that degrade target mRNA through either an RNase H or an siRNAdependant mechanism. Historically, most studies using AS approaches have focused on identifying functions for one gene at a time. However, recent advances in ODs synthesis and the application of high throughput cell-culture-based assays have led to a more global, genome wide approach to gene function studies [16, 42, [148] [149] [150] . It should be noted that PS-ODs have been administered by intravenous infusion to more than 3000 patients and volunteers without any significant indication of activation of the alternative complement cascade. Second-generation ODs also appear to have reduced propensity to activate complement in non-human primates [126] .
The process of identifying AS-ODs for target validation studies can result in a pharmacophore with a well-understood mechanism of action, well-characterized distribution and a safe side effect profile, which could be used as a human therapeutic. A significant advantage of AS approaches to traditional small-molecule-based drug development is the ability to target any gene, irrespective of the protein structure. One example where this has been used to good effect is with the gene survivin. Survivin is a very attractive target for cancer therapeutics, as the protein regulates cell proliferation, apoptosis and is known to be highly expressed in many types of tumors [151] . Considerable efforts have gone into developing small molecule inhibitors against survivin, however to date, no success has been reported [43] . In contrast, an AS-OD inhibitor of survivin has been successfully identified and characterized [152, 153] . Inhibition of survivin expression with this AS results in polyploidy due to a defect in cytokinesis and ultimately induction of apoptosis. More recently, it has been shown that a survivin AS-OD suppresses growth of xenografted tumors. These results have led to a decision to develop the survivin AS as a therapeutic for cancer [154] .
PRACTICAL APPLICATION OF ANTISENSE OLIGONUCLEOTIDES
AS-ODs have the potential of applicability in different areas. One of the major areas of applications is the fundamental research where the introduction of AS-ODs can help to identify and determine the role of a specific gene in a specific physiological process [15, [134] [135] [136] [137] [138] [139] . The use of ASODs to control gene expression has long fascinated researchers because of the potential to rapidly generate potent and specific agents. In the past, AS technology has not always kept pace with expectations, but recent advances in diverse areas are likely to make it a routine and trusted research tool [76] .
AS-ODs and in particular PNAs (third generation), exhibit potential for use in detection of genetic mutations, determination of telomere size, nucleic acid purification, nucleic acid biosensors and several other diagnostic applications [140] [141] [142] . PNAs may also find various interesting applications in chemistry and technology, e.g. as electrochemical biosensors, and in optical data storage [143] [144] [145] . Furthermore, AS-ODs have provided novel opportunities to tailor the composition of plant-derived products, so that they are optimized with respect to food functionality and human dietary needs. In order to exploit this new capability, it is essential for food scientists and nutritionists to define the compositions that would be most desirable for various purposes [146, 147] .
Potential Therapeutic Applications of Antisense Oligonucleotides
AS-ODs can serve as therapeutic molecules in their own right. To this end, ODs have demonstrated pharmacological activity in a number of animal models of human disease. They are being used in various in vitro and in vivo models and are being explored as potential therapeutics against several diseases [155] . A huge number of publications and patents disclosing potential therapeutic applications of ASODs has been published in the last few years. Although it is difficult to cover all potential therapeutics in this article, major areas of AS-ODs therapeutic applications will be addressed in which crossover may be observed.
Attention is being drawn to two important applications of AS-ODs, at least from the pharmaceutical point of view:
Antisense Oligonucleotides as Antiviral Agents
growth and β-lactamase had been obtained by AS-ODs of PNA (18 is a representative), [166] . The use of AS-ODs has emerged as a powerful new approach as antiviral agents. In fact, the initial therapeutic attempts of AS technology were intended to be as an antiviral agent [1,2]. The antiviral activity of AS-ODs is related to the complementation of an AS-OD to repeated or consensus sequences of the genome of a negative strand RNA virus, attached to an activator of RNase L [156] . However, the ribozymes were demonstrated to inhibit viral replication up to 90% in cell; consequently, they were utilized in designing new AS-ODs for therapeutic applications [34, 35] . The approval of the first antiviral AS-OD (Fomivirsen) significantly encouraged the initiation of a new era of rational drug design utilizing a chemistry that allows for the optimization of treatment and opportunity to treat a wide variety of other viral infections. These viruses included influenza A [157] , HBV [158] [159] [160] , HCV [100, 161, 162] , CMV [157] , HPV [163] , RSV [157] , HSV [157] and HIV [164] . Moreover, some of the antiviral AS-ODs are currently in clinical trials, as is shown in section 13.
HGCT-GTT-TC-Lys-NH2 (18) In another study it was found that the mycolyl transferases and other mycobacterial genes are highly promising targets for AS-ODs antitubercular therapy [167, 168] . These results provide a proof of the concept that AS-ODs can be used to develop gene-targeted, designed antibiotics against bacteria. Although much more work is needed to obtain AS-ODs with adequately improved uptake in pathogenic bacteria.
Antisense Oligonucleotides in Apoptosis
Apoptosis is a process by which cells undergo a controlled program of cell death that has been strongly conserved during evolution to prevent uncontrolled cell proliferation [169] . Numerous proteins have been identified that promote apoptosis or have the opposite effect, i.e., protect cells from apoptosis. The upregulation of antiapoptotic proteins in certain disease states, e.g., cancer, may have the serious effect of rendering the disease more resistant to therapeutic intervention. Conversely, the upregulation or pro-apoptotic proteins may also have serious consequences leading to excessive cell loss in degenerative disorders. Several AS-ODs have been designed to target the nucleic acid sequences encoding apoptosis-related proteins. These AS-ODs may be useful in the treatment of cancer, autoimmune disease, viral infections and others. A representative example of this is the inhibition of the expression of nucleotide sequences encoding the human antiapoptotic Bcl-2-related proteins, A-1, MCL-1 and MDM-2.
Antisense Oligonucleotides as Antibacterial Agents
Promising results have been recently suggested a role for AS-ODs in the regulation of bacterial growth [101, 165] . It was found that AS-ODs targeted to either bacterial ribonucleotide reductase or SecA sequences. The expression of these proteins is essential for the growth of many common bacteria. Ribonucleotide reductase provides a balanced supply of deoxynucleotides for DNA synthesis, and SecA is one component of a multicomplex system responsible for the secretion of proteins across the inner membrane of E coli. Significant inhibition of E coli β-galactosidase mediated cell Fig. (13) . Schematic representation of the signal pathways regulating the proliferation and life/death decision in cancer cells. The gray arrows indicate some of the most promising AS-ODs targeted key proteins in pathways [170] . An overexpression of the latter protects cells from p53-mediated apoptosis. Reducing hyperproliferation and treating hyperproliferative conditions associated with overexpression of MDM-2 such as cancer, psoriasis, fibrosis, atherosclerosis and restenosis [156] . Several AS-ODs that target apoptosis are currently in clinical trials, as is shown in section 13.
CNS diseases will address unmet medical needs; some of these diseases are summarized in Table 2 [173, [177] [178] [179] [180] [181] . 
Antisense Oligonucleotides as Anticancer Agents
Neuropathic Pain β-arrestin Particular enthusiasm for AS therapeutic approach derives from the identification of several cancer-associated proteins, which can represent potential targets for a selective anticancer therapy with less toxic side effects than conventional chemotherapy. The preclinical development of several ASODs targeting cancer related genes has proceeded very rapidly. Fig. (13) shows the key signal pathways that regulate the proliferation and the life/death decision in cancer cells [170] .
Glutamate neurotoxicity c-fos
Oxidative cell injury CIRL-1 and -3 AD APP
Brain cancer PKCα and integrin αv
A significant number of studies, as well, suggested that AS-ODs can be extremely valuable tools in the selective block of the expression of neurotransmitter receptors. This will lead to appearance of valuable therapeutic agents to modify disorders involving these receptors. However, efforts should be directed to improve the delivery of these compounds to their targets [182] [183] [184] .
AS-ODs targeting cancer-related genes that interfere with both of these pathways are also shown in Fig. (13) . In fact, considering the multigenic defects of human tumors, the combination of 'agents', targeting specific genes involved in tumor progression, with antineoplastic drugs represents a promising strategy for improving cancer treatment [42] .
11.2.6. Antisense Oligonucleotides in Inflammation Therapeutics Targets for therapeutic AS-ODs include growth factors and receptors, transcription factors, proto-oncogenes, cytokines, cyclin dependent kinase, protein kinases, DNA demethylase and methyltransferase, telomerase, matrix metalloproteinases, angiogenin, integrins, MDM 2, and Bcl-2 family members [171, 172] . Promising results have been achieved by AS-ODs treatment used as anticancer drugs. Table 1 reports some preclinical applications of AS-ODs on human tumors. Furthermore, several AS-ODs for these targets are currently in clinical trials, as is shown in section 13.
With increased understanding of how the immune system functions under normal conditions and a greater appreciation of how dysregulation of immune responses contributes to a variety of inflammatory diseases, a large number of therapeutically useful molecular targets has been identified [185] . AS-ODs have been recently developed that have therapeutic promise for inflammatory diseases. Several inflammatory targets for AS-ODs have been identified and are summarized in Table 3 , [186, 187] . Some of these AS-ODs are currently in clinical trials and others are likely to enter the drug pipeline in the near future. Advances in the field will be greatly facilitated by the genomic revolution [185, 187, 188] .
Antisense Oligonucleotides in CNS Therapeutics
The potential of AS-ODs to treat CNS diseases is enormous, however, there are a number of obstacles to be overcome before AS-ODs can be used effectively in CNS diseases. Basically, of concern is the transport of AS-ODs across the BBB to their site of action. The only efficient CNS AS-ODs delivery method currently available is direct administration into the brain. Despite these problems, a number of potential applications of AS-ODs in CNS therapeutics has been validated in vitro and, in some cases, in vivo [173] [174] [175] [176] . The utility of AS-ODs in management of
Antisense Oligonucleotides in Cardiovascular Therapeutics
AS-ODs in the field of cardiovascular disease would be useful in the treatment of many diseases, including myocardial infarction [189] , prevention of restenosis after angioplasty [190, 191] , rejection in heart transplantation [192, 193] , hypertension and atherosclerosis [194, 195] . Representatives for the target genes involved are E2F, Overall, AS therapy for cardiovascular disease is now apparently not far from a reality, it is time to take a hard look at practical issues that will determine the real clinical potential [191] .
treatment, but it may require multiple applications of the AS-ODs [42] .
Immunostimulatory Side Effects
Immunostimulatory side effects have been observed in animals and humans with the use of the first generation ASODs, as was discussed in section 10 [130] . These problems can be overcome by chemical modifications of AS-ODs as discussed in section 8.1. Typically, modification of the 2' position of the sugar moiety, produces a molecule with increased affinity for RNA and stabilizes against nuclease degradation but with fewer immunostimulatory and other side effects [43, 131] .
Other Therapeutic Application potentials of Antisense Oligonucleotides
As seen previously, there is tremendous interest in ASODs as potential therapeutic agents. In addition to the major therapeutic categories mentioned above, AS-ODs have been explored as potential therapeutics for a variety of diseases including diabetes [196] [197] [198] , pain [184, 199] , psoriasis [200] , myasthenia gravis [201] and even light affections such as hair loss [202] .
Empirical Exercise for Antisense Oligonucleotides Discovery
The most recent AS application as therapeutic tool is aimed to treat SARS, caused by the corona virus, which has impacted the whole world [202] . With the sequencing of the human genome, it is envisaged that many more therapeutic potentialities for AS-ODs will emerge.
The practical aspects of synthesizing and testing a series of AS-ODs should be considered as part of the AS approach for target validation. Identifying the best sequence for AS activity against a target mRNA is largely an empirical exercise. Since not all areas of an mRNA molecule are equally amenable to AS hybridization and because of the inaccessibility of certain hybridization sites in target transcripts, only few complementary ODs can successfully hybridize to a target RNA and inhibit function. This may be attributed to inability to the predict accurate RNA structure in cells owing to, mainly, the secondary or tertiary structures of mRNA or to the proteins bound to the mRNA. The best way to obtain a highly potent AS inhibitor is still to design many AS-ODs to the mRNA of the gene target. It is important to eliminate any ODs that have extensive complementarity to genes other than the desired target. The resulting AS-ODs can then be used in a screen for the most effective inhibitor in a cell culture system. This process requires some investment in the beginning, but it will be time well spent, however, more than one active nucleotide may be yielded [203] .
LIMITATIONS OF PRACTICAL APPLICATIONS OF ANTISENSE OLIGONUCLEOTIDES
Although the AS-ODs technologies offer different choices in terms of their applicability for target validation and gene functionalization and thereby hold tremendous and advantage over other traditional methods of drug discovery, they also have certain limitations. Some of these issues are:
Protein Half-Life
As AS-ODs target RNA and not protein, the biological consequences of the inhibition of a particular gene product are dependent on the normal degradation rate (i.e. half-life) of the already translated protein product. Often, this is not a significant concern, as the half-lives of most proteins are from few hours to a day, but some proteins last up to several days. Therefore, consideration should be given for lag times in such cases, and the most attractive AS targets for determining gene function are those that either induce or encode proteins with a short to moderate half-life. Proteins that have long half-lives can be reduced by AS-ODs
Cellular and In Vivo Delivery
An important hurdle that needs to be overcome for successful AS applications is the cellular uptake of the molecules. In cultured cells, internalization of naked DNA is usually inefficient due to the charged ODs having to cross a hydrophobic cell membrane. A number of methods has therefore been developed for in vitro and in vivo delivery of ODs [18, [204] [205] [206] . By far, the most common and successful delivery systems used are liposomes and charged lipids, which can either encapsulate nucleic acids within their aqueous center or form lipid-nucleic acid complexes as a result of opposing charges. These complexes are usually internalized by endocytosis. For efficient release of the ODs from the endosomal compartment, many transfection reagents contain helper lipids that disrupt the endosomal membrane and help to set the ODs free. A number of macromolar delivery systems has been developed recently that mediate a highly efficient cellular uptake and protect the bound ODs against degradation in biological fluids [18] . [7, 12] . In 1996, only a handful of AS molecules was in clinical trials [207] . Of these six trials, five were only in Phase I. However, the past few years have seen an explosive growth in the number of AS-related clinical trials. Currently, there are nearly 50 AS-ODs in trials for various diseases; up to 10 of these are in phase III, with an additional 20 in Phase II, and representatives of these AS-ODs are given in Table 4 [7,12, 35, 208] . The majority of the drugs in clinical trials are first-generation PS-ODs that are designed to inhibit gene expression through an RNase H mechanism.
The clinical experience to date should be considered part of the beginning of the story of AS treatment, with more clinical trials of new AS drugs expected in the near future. The fuller story, yet to be written, promises to be rich.
CONCLUSION
Despite these successful applications of free AS molecules, higher levels of cellular uptake can usually be achieved by the use of transfection agents. Therefore, the development of delivery systems that mediate efficient cellular uptake and sustained release of the drugs remains one of the major challenges in the AS field.
The AS-ODs have emerged as a valid approach to selectively modulate gene expression by adhering to a strict set of specific rules. A significant advantage of AS-ODs to traditional small-molecule-based drugs development is the ability to target any gene, irrespective of the protein structure. Consequently, AS technologies have gained increasing attention in recent years. Major improvements have been achieved by the development of modified nucleotides that provide high target affinity, enhanced biostability and low toxicity. Since most of the new DNA
CLINICAL TRIALS OF ANTISENSE OLIGONU-CLEOTIDES
To date, one AS-OD (Fomivirsen, 3) has been approved by the FDA for local administration to treat CMV retinitis Fomivirsen", which demonstrate their effectiveness as therapeutic agents, there are still significant hurdles to be overcome. The main barrier is achieving systematic delivery of the AS-ODs to the correct target, within the desired time frame, to achieve functional down regulation of the target gene. These issues are currently being actively addressed and new research will hopefully continue to shed light on ways to increase therapeutic efficacy and specificity. Accordingly, AS-ODs can be expected to be widely used for studies of genes with unknown function, for target validation in drug development and finally for therapeutic purposes of course. The promise of AS-based technology is therefore stronger than ever. 
